News

Pharming understands that the Committee for Medicinal Products for Human Use (CHMP) does not have a specific concern on the safety and efficacy data submitted in the marketing

The carotid endarterectomy (CEA) study enrolled 50 patients and is designed to provide direct evaluation of VIA-2291’s effect on inflammation by analyzing plaque removed from the carotid arteries

The initial closing of the private placement consisted of the sale of 765 shares of series A convertible preferred stock for $1,000 per share. Each share of series

This three party relationship has been established to support a previously established collaboration between Icagen and Pfizer for the discovery of compounds which modulate specific sodium ion channels

Bob Yonke, founder and CEO of Advanced Medical Partners, said: “The combination of AMPI and HealthTronics will allow our physician partners to benefit from HealthTronics’s scale and exclusive

In preclinical research, PNT2258 has shown promising single agent efficacy, combination therapy efficacy and relevant drug-dose response for multiple cancer types including both hematological and solid tumors. ProNAi

The open-label, single-arm Phase I study will assess the tolerability, pharmacokinetic profile and antitumor activity of increasing doses of SGN-33 in combination with Revlimid in up to 30

Safis Solutions is currently interviewing virology laboratories as candidates to conduct the study, which is expected to begin shortly. The purpose of the study is to perfect the

Cenix will apply its expertise in combining high throughput applications of RNAi-based gene silencing technology with high content phenotypic analyses in cultured human cells. The initial project will